Functional evaluation of novel single nucleotide polymorphisms and haplotypes in the promoter regions of CYP1B1 and CYP1A1 genes

Molecular Carcinogenesis

Volumn 37, Issue 3, 2003, Pages 158-169

  Han, Weiguo ^a   Pentecost, Brian T ^a,b   Spivack, Simon D ^a,b,c  

^a WADSWORTH CENTER   (United States)

^b UNIVERSITY AT ALBANY   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

CYP1A1; CYP1B1; Gene regulation; Genetic polymorphism; Lung carcinogenesis; Resveratrol

Indexed keywords

BENZO[A]PYRENE; CIGARETTE SMOKE; GENOMIC DNA; LUCIFERASE; POLYCYCLIC AROMATIC HYDROCARBON; RESVERATROL;

ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; CYP1A1 GENE; CYP1B1 GENE; GENE; GENE AMPLIFICATION; GENE CONSTRUCT; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE INDUCTION; GENE SEQUENCE; GENOME; HAPLOTYPE; HUMAN; IN VIVO STUDY; LUNG CARCINOGENESIS; MOLECULAR CLONING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; REPRESSOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SITE DIRECTED MUTAGENESIS; STATISTICAL SIGNIFICANCE; WILD TYPE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; CELLS, CULTURED; CYTOCHROME P-450 CYP1A1; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; HAPLOTYPES; HUMANS; LUCIFERASES; LUNG NEOPLASMS; MUTAGENESIS, SITE-DIRECTED; MUTATION; POLYCYCLIC HYDROCARBONS, AROMATIC; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RIBONUCLEOTIDE REDUCTASES; STILBENES;

EID: 0042131885     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10132     Document Type: Article

References (45)

1. Guengerich FP, Shimada T. Activation of procarcinogens by human cytochromes P450 enzymes. Mutat Res 1998;400:201-213.
2. Spivack SD, Fasco MJ, Walker VE, Kaminsky LS. The molecular epidemiology of lung cancer. Crit Rev Toxicol 1997;27:319-365.
3. Devereux TR, Domin BA, Philpot RM. Xenobiotic metabolism by isolated pulmonary bronchiolar and alveolar cells. In: Gram TE, editor. Metabolic activation and toxicity of chemical agents to lung tissue and cells. New York: Pergamon Press; 1993. pp 1-24.
4. Mace K, Bowman ED, Vautravers P, Shields PG, Harris CC, Pfeifer AMA. Characterisation of xenobiotic-metabolising enzyme expression in human bronchial mucosa and peripheral lung tissues. Eur J Cancer 1998;34:914-920.
5. Whitlock JP, Jr., Chichester CH, Bedgood RM, et al. Induction of drug-metabolizing enzymes by dioxin. Drug Metab Rev 1997;29:1107-1127.
6. Spivack SD, Hurteau GJ, Reilly AA, Aldous KM, Ding X, Karminsky LS. CYP1B1 expression in human lung. Drug Metab Dispos 2001;29:916-922.
7. Willey JC, Coy EL, Frampton MW, et al. Quantitative RT-PCR measurement of cytochromes P450 1A1,1B1 and 2B7 microsomal epoxide hydrolase, NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am J Respir Cell Biol 1997;17:114-124.
8. Tang YM, Chen GF, Thompson PA, Lin DX, Lang NP, Kadlubar FF. Development of an antipeptide antibody that binds to the C-terminal region of human CYP1B1. Drug Metab Dispos 1999;27:274-280.
9. Shimada T, Hayes CL, Yamazaki H, et al. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res 1996;56:2979-2984.
10. Kim JH, Stansbury KH, Walker NJ, Trush MA, Strickland PT, Sutter TR. Metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis 1998;19:1847-1853.
11. Larsen MC, Angus WG, Brake PB, Eltom SE, Sukow KA, Jefcoate CR. Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: Role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. Cancer Res 1998;58:2366-2374.
12. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17β-Estradiol hydroxylation catalyzed by human cytochrome P4501B1. Proc Natl Acad Sci USA 1996;93:9776-9781.
13. Shimada T, Yamazaki H, Mimura M, et al. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 1996;24:515-522.
14. Kress S, Reichert J, Schwarz M. Functional analysis of the human cytochrome P4501A1 (CYP1A1) gene enhancer. Eur J Biochem 1998;258:803-812.
15. Wo Y-YP, Stewart J, Greenlee WF. Functional analysis of the promoter for the human CYP1B1 gene. J Biol Chem 1997;272:26702-26707.
16. Shehin SE, Stephenson RO, Greenlee WF. Transcriptional regulation of the human CYP1B1 gene. J Biol Chem 2000;275:6770-6776.
17. Murray GI, Melvin WT, Greenlee WF, Burke MD. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 2001;41:297-316.
18. Kouri RE, McKinney CE, Slomiany DJ, Snodgrass DR, Wray NP, McLemore TL. Positive correlation between high aryl hydrocarbon hydroxylase activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res 1982;42:5030-5037.
19. Jacquet M, Lambert V, Baudoux E, Muller M, Kremers P, Gielen J. Correlation between P450 CYP1A1 inducibility, Mspl genotype and lung cancer incidence. Eur J Cancer 1996;32A:1701-1706.
20. Kress S, Greenlee WF. Cell-specific regulation of human CYP1A1 and CYP1B1 genes. Cancer Res 1997;57:1264-1269.
21. Angus WG, Larsen MC, Jefcoate CR. Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: Role of estrogen receptor status. Carcinogenesis 1999;20:947-955.
22. Ciolino HP, Daschner PJ, Yeh GC. Reseveretrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 1998;58:5707-5712.
23. Ciolino HP, Yeh GC. Inhibition of aryl-hydrocarbon-induced cytochrome P450 1A1 enzyme activity and CYP1A1 expression by resveretrol. Mol Pharmacol 1999;56:760-767.
24. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002;61:586-594.
25. Lai J, Vesprini D, Chu W, Jernstrom H, Narod SA. CYP gene polymorphisms and early menarche. Mol Genet Metab 2001;74:449-457.
26. Miyoshi Y, Takahashi Y, Egawa C, Noguchi S. Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J 2002;8:209-215.
27. Wang XL, Greco M, Sim AS, Duarte N, Wang J, Wilcken DE. Effect of CYP1A1 Mspl polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis 2002;162:391-397.
28. Smart J, Daly AK. Variation in induced CYP1A1 level: Relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 2000;10:11-24.
29. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000;97:10483-10488.
30. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-220.
31. Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun 1999;254:739-743.
32. Elattar TM, Virji AS. The effect of red wine and its components on growth and proliferation of human oral squamous carcinoma cells. Anticancer Res 1999;19:5407-5414.
33. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999;20:237-242.
34. Lu R, Serrero G. Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity, and inhibits the growth of human breast cancer cells. J Cell Physiol 1999;179:297-304.
35. Gautam SC, Xu YX, Dumaguin M, Janakiraman N, Chapman RA. Resveratrol selectively inhibits leukemia cells: A prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant 2000;25:639-645.
36. Prescott E, Gronbaek M, Becker U, Sorensen TI. Alcohol intake and the risk of lung cancer: Influence of type of alcoholic beverage. Am J Epidemiol 1999;149:463-470.
37. Mollerup S, Ovrebo S, Haugen A. Lung carcinogenesis: Resveratrol modulates the expression of genes involved in the metabolism of PAH in human bronchial epithelial cells. Int J Cancer 2001;92:18-25.
38. Georgopoulos K, Bigby M, Wang JH, et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell 1994;79:143-156.
39. Georgopoulos K, Winandy S, Avitahl N. The role of the Ikaros gene in lymphocyte development and homeostasis. Annu Rev Immunol 1997;15:155-176.
40. Brown KE, Guest SS, Smale ST, Hahm K, Merkenschlager M, Fisher AG. Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochromatin. Cell 1997;91:845-854.
41. Klug CA, Morrison SJ, Masek M, Hahm K, Smale ST, Weissman IL. Hematopoietic stem cells and lymphoid progenitors express different Ikaros isoforms, and Ikaros is localized to heterochromatin in immature lymphocytes. Proc Natl Acad Sci USA 1998;95:657-662.
42. Sun L, Liu A, Georgopoulos K. Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development. EMBO J 1996;15:5358-5369.
43. Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell 1995;83:289-299.
44. Georgopoulos K, Moore DD, Derfler B. Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science 1992;258:808-812.
45. Sun L, Heerema N, Crotty L, et al. Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci USA 1999;96:680-685.